Open AccessProtein modification by biotinylated amoxicillin: usefulness in studies on allergy towards beta‐lactams
Author(s) -
Ariza Adriana,
Collado Daniel,
Vida Yolanda,
Montañez María Isabel,
PérezInestrosa Ezequiel,
Blanca Miguel,
Torres María José,
Cañada Javier,
PérezSala Dolores
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s3-p37
Subject(s) - biotinylation , amoxicillin , antibody , streptavidin , western blot , immunoglobulin e , microbiology and biotechnology , immune system , medicine , biotin , chemistry , immunology , biochemistry , antibiotics , biology , gene
Background Beta-lactam (BLs) antibiotics are among the drugs most frequently eliciting allergic reactions, thus posing an important clinical problem. Protein haptenation plays a key role in immunological reactions to BLs and this process is considered necessary for the activation of the immune system. Therefore, it is of interest to develop tools to monitor this process. We have synthesized a biotinylated amoxicillin derivative (AX-B) to be used in the characterization of protein haptenation by amoxicillin (AX). Methods AX-B was obtained binding a biotin moiety at the lateral chain of AX. The recognition of AX-B by IgE of allergic patients was analyzed by RAST inhibition. AX and AX-B were used for the in vitro modification of proteins in serum and in cell culture. Modified proteins were separated by SDS-PAGE and detected by Western blot using an anti-AX antibody (for AX-modification) or HRP-streptavidin (for AX-B-modification). Distribution of intracellular protein adducts with AX-B was analyzed by confocal microscopy. Results AX-B showed a chemical reactivity similar to AX and competition studies suggested that AX-B and AX can modify the same targets. AX and AX-B behaved similarly in RAST inhibition studies with sera of patients with nonselective allergy to BLs, whereas competition by AX-B was poorer with sera of AX-selective patients. AX-B allowed the detection of protein adducts with high sensitivity. This derivative bound to all of the previously identified major AX targets in serum but made possible to detect some new targets. In addition, in cell culture, AX-B protein adducts could be detected intracellularly. Conclusions AX-B may constitute a valuable tool for the identification of AX targets with high sensitivity. The identity of novel AX-B targets will be the subject of future studies.